Certain species of vaginal bacteria can inhibit the efficacy of the topical microbicide tenofovir, which is used to prevent HIV, by breaking it down before it is absorbed, reports an international team of investigators in Science.
Women using the vaginal antiretroviral gel tenofovir to prevent acquisition of HIV have experienced inconsistent results. Variability in adherence has been shown to be a factor in the diverse trial outcomes, but little is known about the biological factors that may contribute to variable results.
Friedrich M. Vaginal Microbiome Affects Efficacy of HIV Microbicide. JAMA. 2017;318(3):231. doi:10.1001/jama.2017.9091
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: